Cartesian Therapeutics (RNAC) Other Accumulated Expenses (2015 - 2016)
Cartesian Therapeutics (RNAC) reported Other Accumulated Expenses of $831000.0 for Q2 2016, up 272.65% quarter-over-quarter from $223000.0 in Q4 2015.
Cartesian Therapeutics (RNAC) Other Accumulated Expenses (2015 - 2016) Analysis & Trends
Cartesian Therapeutics (RNAC) has 2 years of Other Accumulated Expenses data on file, last reported at $831000.0 in Q2 2016.
- Other Accumulated Expenses for Q2 2016 came in at $831000.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2016 was $831000.0 (changed N/A YoY), and the FY2015 annual result was $223000.0, changed N/A from the prior year.
- Other Accumulated Expenses grew to $831000.0 in Q2 2016 per RNAC's latest filing, from $223000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $831000.0 in Q2 2016 and troughed at $223000.0 in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 831,000.00 |
| Dec 31, 2015 | 223,000.00 |